The double-blind, randomized and placebo-controlled trial will recruit around 48 healthy subjects and 20 HCV genotype 1 treatment naive patients in the US.
Achillion president and CEO Michael Kishbauch said over the next few quarters, they plan to achieve human proof-of-concept on ACH-2928 and to advance an additional NS5A inhibitor into clinical development.
"Furthermore, we intend to obtain additional clinical results from our protease inhibitor programs including 12-week EVR results from the Phase 2a trial with ACH-1625 and to establish clinical proof-of-concept on ACH-2684, our pan-genotypic agent being evaluated in Phase 1," Kishbauch said.